Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway.
暂无分享,去创建一个
J. Wan | X. Gong | Ge Kuang | Shengwang Wu | Jin Liu | Hao Liu | Xinru Yin | Jun Hu | Ningman Jiang
[1] M. Roden,et al. Mitochondrial alterations in fatty liver diseases. , 2022, Journal of hepatology.
[2] D. Brenner,et al. Molecular and cellular mechanisms of liver fibrosis and its regression , 2020, Nature Reviews Gastroenterology & Hepatology.
[3] Wen Liu,et al. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice , 2019, Cellular & Molecular Immunology.
[4] M. Shariati,et al. Chrysin: Pharmacological and therapeutic properties. , 2019, Life sciences.
[5] C. Dinu‐Pîrvu,et al. Pharmacokinetics of B-Ring Unsubstituted Flavones , 2019, Pharmaceutics.
[6] Jun Yu,et al. Bone marrow‐derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells , 2019, The Journal of pathology.
[7] G. Liebisch,et al. iPla2β deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[8] X. Chen,et al. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease , 2019, The Journal of international medical research.
[9] Z. Younossi. Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.
[10] G. Palladini,et al. Animal Models of Steatosis (NAFLD) and Steatohepatitis (NASH) Exhibit Hepatic Lobe-Specific Gelatinases Activity and Oxidative Stress , 2019, Canadian journal of gastroenterology & hepatology.
[11] Sally A El Awdan,et al. Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. , 2019, Chemico-biological interactions.
[12] P. Kamath,et al. Burden of liver diseases in the world. , 2019, Journal of hepatology.
[13] F. Bessone,et al. Molecular pathways of nonalcoholic fatty liver disease development and progression , 2018, Cellular and Molecular Life Sciences.
[14] D. Schuppan,et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.
[15] A. Garg,et al. Development and evaluation of Chrysin-Phospholipid complex loaded solid lipid nanoparticles - storage stability and in vitro anti-cancer activity , 2018, Journal of microencapsulation.
[16] Hao Zhou,et al. Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy , 2018, Redox biology.
[17] A. Feldstein,et al. Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.
[18] M. Konerman,et al. Pharmacotherapy for NASH: Current and emerging. , 2018, Journal of hepatology.
[19] G. Sulaiman,et al. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity , 2018, Artificial cells, nanomedicine, and biotechnology.
[20] M. Yoneda,et al. Current and future pharmacological therapies for NAFLD/NASH , 2017, Journal of Gastroenterology.
[21] S. Rezaee,et al. An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[22] S. Friedman,et al. Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.
[23] A. Bast,et al. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease , 2017, Critical reviews in food science and nutrition.
[24] Abolfazl Akbarzadeh,et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications , 2017, Artificial cells, nanomedicine, and biotechnology.
[25] N. Oku. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases. , 2017, Biological & pharmaceutical bulletin.
[26] T. Giri,et al. Nano-encapsulation of capsaicin on lipid vesicle and evaluation of their hepatocellular protective effect. , 2016, International journal of biological macromolecules.
[27] A. Alanazi,et al. Targeted nano-delivery of novel omega-3 conjugate against hepatocellular carcinoma: Regulating COX-2/bcl-2 expression in an animal model. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[28] U. Haberkorn,et al. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[29] Jianqing Gao,et al. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo , 2016, International journal of nanomedicine.
[30] Alexis M. Kalergis,et al. Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.
[31] G. Musso,et al. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.
[32] A. Hermenean,et al. Chrysin attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. , 2015, Chemico-biological interactions.
[33] T. Pihlajaniemi,et al. Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences , 2015, Redox biology.
[34] J. Antoun,et al. Hepatic TLR4 signaling in obese NAFLD. , 2015, American journal of physiology. Gastrointestinal and liver physiology.
[35] J. González‐Gallego,et al. Flavonoids and Related Compounds in Non-Alcoholic Fatty Liver Disease Therapy. , 2015, Current medicinal chemistry.
[36] F. Tacke,et al. Roles for chemokines in liver disease. , 2014, Gastroenterology.
[37] Z. Gu,et al. Nanoparticles generated by PEG-Chrysin conjugates for efficient anticancer drug delivery. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[38] Zhiyuan Niu,et al. Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARγ. , 2014, Biochemical pharmacology.
[39] Zheng Zhang,et al. The role of neutrophils in the development of liver diseases , 2014, Cellular and Molecular Immunology.
[40] J. Odin,et al. Toll‐like receptors and liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[41] Rainer H Müller,et al. Nanotoxicological classification system (NCS) - a guide for the risk-benefit assessment of nanoparticulate drug delivery systems. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[42] E. Seki,et al. Toll‐like receptors in alcoholic liver disease, non‐alcoholic steatohepatitis and carcinogenesis , 2013, Journal of gastroenterology and hepatology.
[43] S. Akira,et al. Pattern Recognition Receptors and Inflammation , 2010, Cell.
[44] S. Kim,et al. Suppression of the TRIF-dependent signaling pathway of Toll-like receptors by luteolin. , 2009, Biochemical pharmacology.
[45] W. Yeh,et al. LPS/TLR4 signal transduction pathway. , 2008, Cytokine.
[46] T. Walle,et al. Cancer chemopreventive properties of orally bioavailable flavonoids--methylated versus unmethylated flavones. , 2007, Biochemical pharmacology.
[47] I. Leclercq,et al. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. , 2007, Journal of hepatology.
[48] Shizuo Akira,et al. Toll-like receptor signalling , 2004, Nature Reviews Immunology.
[49] G. Jacquemin. [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.
[50] P. Halushka,et al. Disposition and metabolism of the flavonoid chrysin in normal volunteers. , 2001, British journal of clinical pharmacology.
[51] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[52] V. Natesan,et al. Chrysin: Sources, beneficial pharmacological activities, and molecular mechanism of action. , 2018, Phytochemistry.
[53] T. Ishida,et al. Liposomal Delivery Systems: Design Optimization and Current Applications. , 2017, Biological & pharmaceutical bulletin.